All In Biotech

Drug Trial Radar · NCT01141491

Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free

A Randomized, Multicenter, Double-Blind, Phase II Trial of a KLH Conjugated Trivalent Ganglioside Vaccine Containing GM2, GD2 Lactone, and GD3 Lactone With the Immunological Adjuvant OPT-821 Versus OPT-821 Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free

Last checked: Nov 19, 2026Latest source record: Apr 12, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 136 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

136

Actual

Start

Jun 2010

Primary completion

Sep 2013

Study completion Mar 10, 2017

Sponsor

Lead sponsor
MabVax Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jun 10, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Sarcoma patients are at high risk for their cancer to recur even when the sarcoma has been removed surgically or treated with radiation or chemotherapy. The patients in the study will be randomized (like flipping a coin) to receive either a vaccine that is combined with an immune system stimulant or the immune system stimulant alone. The immune system stimulant is called OPT-821 and is an immunological booster. The trivalent vaccine is being developed to teach the patient's immune system to recognize 3 types of sugars called GM2, GD2 and GD3 that are found primarily on the surface of sarcoma cells. If the trivalent vaccine can stimulate the patient's immune system to develop antibodies which recognize and target the GM2, GD2 and GM3 sugars, then the patient's antibodies could attack and kill any remaining sarcoma cells potentially preventing the recurrence of sarcoma.

Conditions

  • Sarcoma

Interventions

  • Trivalent ganglioside vaccineBiological

    Patients will be given 10 injections of ganglioside vaccine plus adjuvant OPT-821 as a 1.0 ml subcutaneous injection in an outpatient setting at Visit Weeks 1, 2, 3, 8, 16, 28, 40, 52, 68 and 84

  • OPT-821Biological

    Patients will be given 10 injections of adjuvant OPT-821 as a 1.0 ml subcutaneous injection in an outpatient setting at Visit Weeks 1, 2, 3, 8, 16, 28, 40, 52, 68 and 84

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free SurvivalTime frame: 3-years

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • UCLA Medical Center

    Los Angeles, California

  • University of Colorado (Denver)

    Denver, Colorado

  • Winship Cancer Institute at Emory Midtown

    Atlanta, Georgia

  • Northwestern University - Robert H. Lurie Comprehensive Cancer Center

    Chicago, Illinois

  • University of Iowa Hospitals and Clinic

    Iowa City, Iowa

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • University of Michigan Hospital

    Ann Arbor, Michigan

  • Washington University School of Medicine

    St Louis, Missouri

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • Cleveland Clinic

    Cleveland, Ohio

  • Oregon Health & Sciences University

    Portland, Oregon

  • University of Pittsburg Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • Fred Hutchinson Cancer Research Center/Seattle Cancer Care

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.